Alzheimer's, Ozempic

Ozempic May Reduce the Risk of Alzheimer’s. That’s Huge for Novo Nordisk.
Ozempic and Wegovy, the two brand names under which the company sells the GLP-1 drug semaglutide, are already blockbusters.
Ozempic may significantly lower the risk of Alzheimer’s disease — here’s how
Nearly 7 million Americans 65 and older are living with Alzheimer’s disease, which gradually destroys memory and thinking skills and the ability to perform daily tasks.
Ozempic linked to lower Alzheimer's risk in people with Type 2 diabetes
Semaglutide, the active ingredient in Ozempic and Wegovy, appeared to reduce the risk of Alzheimer’s disease in people with Type 2 diabetes, according to a study published Thursday in the journal Alzheimer’s & Dementia.
Active ingredient in Ozempic, Wegovy may reduce risk of Alzheimer's disease: Study
Semaglutide, the active ingredient found in Ozempic and Wegovy, may reduce the risk of Alzheimer’s disease, a new study published Thursday morning finds.
Ozempic linked to lower risk of Alzheimer’s diagnosis in observational study
In an observational study, Novo Nordisk’s drug Ozempic was linked to a lower risk of getting diagnosed with Alzheimer’s among people with type 2 diabetes.
Ozempic, Wegovy might lower Alzheimer's risk in Type 2 diabetics
People with Type 2 diabetes taking semaglutide appeared to have a significantly lower risk of developing Alzheimer's compared to patients taking seven other diabetes drugs, researchers reported.
Ozempic, Wegovy Might Help Lower Alzheimer's Risk in People With Diabetes
By Dennis Thompson HealthDay Reporter THURSDAY, Oct. 24, 2024 (HealthDay News) -- Add Alzheimer’s disease to the list of conditions that might benefit from the revolutionary diabetes drug Ozempic, a new study says.
Novo Nordisk's diabetes drug Ozempic may reduce the risk of Alzheimer's disease, study says
The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer’s diagnosis in diabetes patients.
HR Dive56m
Employees are asking about GLP-1 coverage. What should employers do?
For GLP-1 treatment in particular, employers “need to make sure the coverage is married with a patient engagement program, ...
The Economist18h
It’s not just obesity. Drugs like Ozempic will change the world
Already one in eight American adults has been on glp-1 drugs. Novo Nordisk, maker of semaglutide, branded Ozempic for ...
Healthline2d
How Ozempic, GLP-1 Weight Loss Drugs Affect the Brain to Curb Substance Misuse
A recent study found significant reductions in opioid overdose and alcohol misuse among people taking GLP-1 drugs like ...
The Maker of Ozempic Is Trying to Block Compounded Versions of Its Blockbuster Drug
Novo Nordisk has asked the FDA to block production of compounded copies of Ozempic, arguing that it’s too difficult to do ...
The Economist18h
GLP-1s like Ozempic are among the most important drug breakthroughs ever
More recently they have become a wildly popular way for people to lose weight. But in March semaglutide (a GLP-1 receptor ...
New guidance for stroke prevention includes Ozempic, other weight loss drugs
For the first time in a decade, the American Heart Association and American Stroke Association issued new recommendations for ...
Diabetes patients worry about insulin shortages as Ozempic use skyrockets
The insulin is facing supply shortages as diabetes patients increasingly turn to GLP-1 weight loss drugs such as Ozempic and ...
Ozempic and Wegovy are trimming waistlines—and showing how quickly U.S. health care can turn into a gold rush
The GLP-1 phenomenon is making the fragmentation and dysfunction of the U.S. health care system even more apparent.